Compare · ALGN vs COCH
ALGN vs COCH
Side-by-side comparison of Align Technology Inc. (ALGN) and Envoy Medical Inc. (COCH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALGN and COCH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ALGN is the larger of the two at $12.78B, about 219.1x COCH ($58.3M).
- Over the past year, ALGN is down 7.4% and COCH is down 52.0% - ALGN leads by 44.6 points.
- COCH has been more active in the news (8 items in the past 4 weeks vs 6 for ALGN).
- ALGN has more recent analyst coverage (25 ratings vs 2 for COCH).
- Company
- Align Technology Inc.
- Envoy Medical Inc.
- Price
- $178.51-1.14%
- $0.76+9.15%
- Market cap
- $12.78B
- $58.3M
- 1M return
- +1.23%
- +19.67%
- 1Y return
- -7.35%
- -51.98%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2001
- 2021
- News (4w)
- 6
- 8
- Recent ratings
- 25
- 2
Align Technology Inc.
Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
Latest ALGN
- Operation Smile Announces Align Technology as Title Sponsor of 34th International Student Leadership Conference for Sixth Year
- BMO Capital Markets initiated coverage on Align Tech with a new price target
- Align Technology Inc. filed SEC Form 8-K: Leadership Update
- Align Technology to Announce Second Quarter 2026 Results on July 29, 2026
- Align Technology Statement on European Commission Proceeding
- Align Technology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Align Technology Announces Board Leadership Transition. C. Raymond Larkin, Jr. to Retire as Chairman and Kevin Conroy to be Appointed Chairman Effective July 1, 2026
- Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research
- SEC Form SD filed by Align Technology Inc.
- Director Vitalone Britt J. converted options into 1,443 shares (SEC Form 4)
Latest COCH
- Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
- Envoy Medical Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device
- Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
- Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Envoy Medical Terminates At-the-Market (ATM) Equity Facility
- SEC Form 4 filed by Chief Executive Officer Lucas Brent T.
- Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
- Envoy Medical to Present at Investor Conferences on June 25th
- SEC Form EFFECT filed by Envoy Medical Inc.